Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.
Molecules. 2022 Jun 24;27(13):4079. doi: 10.3390/molecules27134079.
VEGFR-2, the subtype receptor tyrosine kinase (RTK) responsible for angiogenesis, is expressed in various cancer cells. Thus, VEGFER-2 inhibition is an efficient approach for the discovery of new anticancer agents. Accordingly, a new set of nicotinamide derivatives were designed and synthesized to be VEGFR-2 inhibitors. The chemical structures were confirmed using IR, H-NMR, and C-NMR spectroscopy. The obtained compounds were examined for their anti-proliferative activities against the human cancer cell lines (HCT-116 and HepG2). VEGFR-2 inhibitory activities were determined for the titled compounds. Compound exhibited the strongest anti-proliferative activities with IC values of 5.4 and 7.1 µM against HCT-116 and HepG2, respectively. Interestingly, compound was the most potent VEGFR-2 inhibitor with an IC value of 77.02 nM (compare to sorafenib: IC = 53.65 nM). Treatment of HCT-116 cells with compound produced arrest of the cell cycle at the G0-G1 phase and a total apoptosis increase from 3.05 to 19.82%-6.5-fold in comparison to the negative control. In addition, compound caused significant increases in the expression levels of caspase-8 (9.4-fold) and Bax (9.2-fold), and a significant decrease in the Bcl-2 expression level (3-fold). The effects of compound on the levels of the immunomodulatory proteins (TNF-α and IL-6) were examined. There was a marked decrease in the level of TNF-α (92.37%) compared to the control (82.47%) and a non-significant reduction in the level of IL-6. In silico docking, molecular dynamics simulations, and MM-PBSA studies revealed the high affinity, the correct binding, and the optimum dynamics of compound 8 inside the active site of VEGFR-2. Finally, in silico ADMET and toxicity studies indicated acceptable values of drug-likeness. In conclusion, compound has emerged as a promising anti-proliferative agent targeting VEGFR-2 with significant apoptotic and immunomodulatory effects.
VEGFR-2,负责血管生成的亚型受体酪氨酸激酶 (RTK),在各种癌细胞中表达。因此,VEGFER-2 抑制是发现新的抗癌药物的有效方法。相应地,设计并合成了一组新的烟酰胺衍生物作为 VEGFR-2 抑制剂。使用 IR、H-NMR 和 C-NMR 光谱确认了化学结构。测试了获得的化合物对人癌细胞系 (HCT-116 和 HepG2) 的抗增殖活性。测定了标题化合物的 VEGFR-2 抑制活性。化合物 表现出最强的抗增殖活性,对 HCT-116 和 HepG2 的 IC 值分别为 5.4 和 7.1µM。有趣的是,化合物 是最强效的 VEGFR-2 抑制剂,IC 值为 77.02 nM(与索拉非尼相比:IC = 53.65 nM)。用化合物 处理 HCT-116 细胞会导致细胞周期停滞在 G0-G1 期,与阴性对照相比,总凋亡增加 3.05 至 19.82%-6.5 倍。此外,化合物 导致 caspase-8(9.4 倍)和 Bax(9.2 倍)的表达水平显着增加,Bcl-2 表达水平显着降低(3 倍)。还检查了化合物 对免疫调节蛋白(TNF-α和 IL-6)水平的影响。与对照(82.47%)相比,TNF-α 的水平显着降低(92.37%),而 IL-6 的水平没有显着降低。基于分子的对接、分子动力学模拟和 MM-PBSA 研究表明,化合物 8 在 VEGFR-2 的活性部位具有高亲和力、正确结合和最佳动力学。最后,基于计算机的 ADMET 和毒性研究表明药物相似性具有可接受的值。总之,化合物 作为一种有前途的 VEGFR-2 靶向抗增殖剂,具有显着的凋亡和免疫调节作用。